Citadel Advisors’s Evolent Health EVH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $52.4K | Sell |
23,000
-31,700
| -58% | -$101K | ﹤0.01% | 12390 |
|
|
2025
Q4 | $219K | Buy |
54,700
+33,500
| +158% | +$186K | ﹤0.01% | 10848 |
|
|
2025
Q3 | $179K | Buy |
+21,200
| New | +$206K | ﹤0.01% | 11375 |
|
|
2025
Q2 | – | Sell |
-125,800
| Closed | -$1.19M | – | 13221 |
|
|
2025
Q1 | $1.19M | Sell |
125,800
-68,100
| -35% | -$688K | ﹤0.01% | 6572 |
|
|
2024
Q4 | $2.18M | Sell |
193,900
-26,500
| -12% | -$466K | ﹤0.01% | 5450 |
|
|
2024
Q3 | $6.23M | Buy |
220,400
+49,800
| +29% | +$1.28M | ﹤0.01% | 3600 |
|
|
2024
Q2 | $3.26M | Buy |
170,600
+147,600
| +642% | +$3.77M | ﹤0.01% | 4437 |
|
|
2024
Q1 | $754K | Sell |
23,000
-4,700
| -17% | -$150K | ﹤0.01% | 7512 |
|
|
2023
Q4 | $915K | Buy |
27,700
+13,600
| +96% | +$385K | ﹤0.01% | 6852 |
|
|
2023
Q3 | $384K | Buy |
14,100
+2,900
| +26% | +$80.6K | ﹤0.01% | 8644 |
|
|
2023
Q2 | $339K | Sell |
11,200
-30,300
| -73% | -$980K | ﹤0.01% | 8773 |
|
|
2023
Q1 | $1.35M | Buy |
41,500
+10,400
| +33% | +$329K | ﹤0.01% | 6138 |
|
|
2022
Q4 | $873K | Sell |
31,100
-28,600
| -48% | -$820K | ﹤0.01% | 7069 |
|
|
2022
Q3 | $2.15M | Buy |
59,700
+40,200
| +206% | +$1.42M | ﹤0.01% | 5456 |
|
|
2022
Q2 | $599K | Buy |
19,500
+4,900
| +34% | +$143K | ﹤0.01% | 8227 |
|
|
2022
Q1 | $472K | Sell |
14,600
-9,800
| -40% | -$257K | ﹤0.01% | 9529 |
|
|
2021
Q4 | $675K | Sell |
24,400
-25,900
| -51% | -$743K | ﹤0.01% | 8921 |
|
|
2021
Q3 | $1.56M | Buy |
50,300
+24,500
| +95% | +$588K | ﹤0.01% | 6994 |
|
|
2021
Q2 | $545K | Sell |
25,800
-13,300
| -34% | -$266K | ﹤0.01% | 9879 |
|
|
2021
Q1 | $790K | Buy |
39,100
+15,000
| +62% | +$285K | ﹤0.01% | 8674 |
|
|
2020
Q4 | $386K | Buy |
24,100
+6,700
| +39% | +$88.6K | ﹤0.01% | 8631 |
|
|
2020
Q3 | $216K | Buy |
17,400
+1,000
| +6% | +$11.8K | ﹤0.01% | 8683 |
|
|
2020
Q2 | $117K | Buy |
+16,400
| New | +$110K | ﹤0.01% | 8901 |
|
|
2020
Q1 | – | Sell |
-11,300
| Closed | -$102K | – | 9730 |
|
|
2019
Q4 | $102K | Sell |
11,300
-245,800
| -96% | -$2M | ﹤0.01% | 8539 |
|
|
2019
Q3 | $1.85M | Buy |
257,100
+239,000
| +1,320% | +$1.72M | ﹤0.01% | 4596 |
|
|
2019
Q2 | $144K | Buy |
+18,100
| New | +$214K | ﹤0.01% | 8378 |
|
|
2018
Q4 | – | Sell |
-19,300
| Closed | -$548K | – | 9275 |
|
|
2018
Q3 | $548K | Buy |
+19,300
| New | +$460K | ﹤0.01% | 6544 |
|
|
2017
Q2 | – | Sell |
-12,500
| Closed | -$279K | – | 7621 |
|
|
2017
Q1 | $279K | Buy |
+12,500
| New | +$240K | ﹤0.01% | 5981 |
|
Other funds holding EVH
CCM
RF
EC
VCM
RSCM
Citadel Advisors's EVH Position: Q1 2026 in Review
Citadel Advisors reduced its Evolent Health (EVH) stake by 62% in Q1 2026, selling an estimated $3.65M and leaving 705,222 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #6570.
Citadel Advisors first reported a position in EVH in Q2 2015 and has held it in 40 quarters since. The position peaked at $73M in Q4 2022. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.
- Citadel Advisors held 705,222 shares of Evolent Health worth $1.61M as of Q1 2026.
- Citadel Advisors sold 1,149,795 Evolent Health shares in Q1 2026, an estimated $3.65M.
- Evolent Health made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6570 holding.
- Citadel Advisors first reported a position in Evolent Health in Q2 2015 and has held it in 40 quarters since.
- Citadel Advisors's Evolent Health position peaked at $73M in Q4 2022.
- 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.